EGFR and neoplasm: CGS analysis of genetic alterations in 201 primary CRCs revealed important genetic differences in relation to tumor sidedness: that there are genetic alterations in RCRC that are distinct from LCRC, and that CRCs wild-type in TK receptors and the RAS and PI3K pathways (termed “all wild-type” tumors and theoretically more likely to respond to anti-EGFR therapy), were significantly less common amongst RCRC.